M-J J Mangen1, H Stibbe2, A Urbanus3, E C Siedenburg4, Q Waldhober5, G A de Wit6, J E van Steenbergen7. 1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands. Electronic address: marie-josee.mangen@rivm.nl. 2. University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands. 3. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. 4. Public Health Service Amsterdam, Amsterdam, The Netherlands. 5. Netherlands Association of Community Health Services, Utrecht, The Netherlands. 6. University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands; Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. 7. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Centre of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of the on-going decentralised targeted hepatitis B vaccination program for behavioural high-risk groups operated by regional public health services in the Netherlands since 1-November-2002. Target groups for free vaccination are men having sex with men (MSM), commercial sex workers (CSW) and hard drug users (HDU). Heterosexuals with a high partner change rate (HRP) were included until 1-November-2007. METHODS: Based on participant, vaccination and serology data collected up to 31-December-2012, the number of participants and program costs were estimated. Observed anti-HBc prevalence was used to estimate the probability of susceptible individuals per risk-group to become infected with hepatitis B virus (HBV) in their remaining life. We distinguished two time-periods: 2002-2006 and 2007-2012, representing different recruitment strategies and target groups. Correcting for observed vaccination compliance, the number of future HBV-infections avoided was estimated per risk-group. By combining these numbers with estimates of life-years lost, quality-of-life losses and healthcare costs of HBV-infections - as obtained from a Markov model-, the benefit of the program was estimated for each risk-group separately. RESULTS: The overall incremental cost-effectiveness ratio of the program was €30,400/QALY gained, with effects and costs discounted at 1.5% and 4%, respectively. The program was more cost-effective in the first period (€24,200/QALY) than in the second period (€42,400/QALY). In particular, the cost-effectiveness for MSM decreased from €20,700/QALY to €47,700/QALY. DISCUSSION AND CONCLUSION: This decentralised targeted HBV-vaccination program is a cost-effective intervention in certain unvaccinated high-risk adults. Saturation within the risk-groups, participation of individuals with less risky behaviour, and increased recruitment investments in the second period made the program less cost-effective over time. The project should therefore discus how to reduce costs per risk-group, increase effects or when to integrate the vaccination in regular healthcare.
BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of the on-going decentralised targeted hepatitis B vaccination program for behavioural high-risk groups operated by regional public health services in the Netherlands since 1-November-2002. Target groups for free vaccination are men having sex with men (MSM), commercial sex workers (CSW) and hard drug users (HDU). Heterosexuals with a high partner change rate (HRP) were included until 1-November-2007. METHODS: Based on participant, vaccination and serology data collected up to 31-December-2012, the number of participants and program costs were estimated. Observed anti-HBc prevalence was used to estimate the probability of susceptible individuals per risk-group to become infected with hepatitis B virus (HBV) in their remaining life. We distinguished two time-periods: 2002-2006 and 2007-2012, representing different recruitment strategies and target groups. Correcting for observed vaccination compliance, the number of future HBV-infections avoided was estimated per risk-group. By combining these numbers with estimates of life-years lost, quality-of-life losses and healthcare costs of HBV-infections - as obtained from a Markov model-, the benefit of the program was estimated for each risk-group separately. RESULTS: The overall incremental cost-effectiveness ratio of the program was €30,400/QALY gained, with effects and costs discounted at 1.5% and 4%, respectively. The program was more cost-effective in the first period (€24,200/QALY) than in the second period (€42,400/QALY). In particular, the cost-effectiveness for MSM decreased from €20,700/QALY to €47,700/QALY. DISCUSSION AND CONCLUSION: This decentralised targeted HBV-vaccination program is a cost-effective intervention in certain unvaccinated high-risk adults. Saturation within the risk-groups, participation of individuals with less risky behaviour, and increased recruitment investments in the second period made the program less cost-effective over time. The project should therefore discus how to reduce costs per risk-group, increase effects or when to integrate the vaccination in regular healthcare.
Keywords:
Commercial sex workers; Cost-effectiveness; Economic evaluation; Hard drug users; Hepatitis B virus vaccination; High-risk group; Men having sex with men
Authors: Berend J van Welzen; Colette Smit; Anders Boyd; Faydra I Lieveld; Tania Mudrikova; Peter Reiss; Annemarie E Brouwer; Andy I M Hoepelman; Joop E Arends Journal: Open Forum Infect Dis Date: 2020-06-25 Impact factor: 3.835
Authors: Anita W M Suijkerbuijk; Albert Jan van Hoek; Jelle Koopsen; Robert A de Man; Marie-Josee J Mangen; Hester E de Melker; Johan J Polder; G Ardine de Wit; Irene K Veldhuijzen Journal: PLoS One Date: 2018-11-08 Impact factor: 3.240
Authors: Maria Xiridou; Philippe Adam; Annemarie Meiberg; Maartje Visser; Amy Matser; John de Wit; Eline Op de Coul Journal: Vaccine Date: 2022-07-04 Impact factor: 4.169